发明名称 USE OF NIGERICIN TO TREAT AND PREVENT VACCINIA VIRUS INFECTIONS
摘要 <p>Poxviruses remain a significant public health concern due to their potential use as bioterrorist agents and the spread of animal borne poxviruses, such as monkeypox virus, to humans. Thus, the identification of small molecule inhibitors of poxvirus replication is warranted. Vaccinia virus is the prototypic member of the Orthopoxvirus genus, which also includes variola and monkeypox virus. In this study, we demonstrate that the carboxylic ionophore nigericin is a potent inhibitor of vaccinia virus replication in several human cell lines, in HeLa cells, we found that the 50% inhibitory concentration of nigericin against vaccinia virus was 7.9 nM, with a selectivity index of 1038. We present data demonstrating that nigericin targets vaccinia virus replication at a post-entry stage. While nigericin moderately inhibits both early vaccinia gene transcription and translation, viral DNA replication and intermediate and late gene expression are severely compromised in the presence of nigericin. Our results demonstrate that nigericin has the potential to be further developed into an effective antiviral to treat poxvirus infections.</p>
申请公布号 EP2618825(A1) 申请公布日期 2013.07.31
申请号 EP20110827867 申请日期 2011.09.16
申请人 HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH 发明人 MYSKIW, CHAD;CAO, JINGXIN;HE, RUNTAO
分类号 A61K31/35;A61P31/20 主分类号 A61K31/35
代理机构 代理人
主权项
地址